- Home
- VMD vs CNTX Comparison
VMD vs CNTX Comparison
Compare VMD & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VMD | CNTX |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 313.3M | 283.9M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VMD | CNTX |
|---|---|---|
| Price | $9.74 | $2.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 263.8K | ★ 677.2K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.14 | 17.39 |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $270,280,000.00 | N/A |
| Revenue This Year | $17.88 | N/A |
| Revenue Next Year | $14.98 | N/A |
| P/E Ratio | $25.86 | ★ N/A |
| Revenue Growth | ★ 20.52 | N/A |
| 52 Week Low | $5.93 | $0.49 |
| 52 Week High | $10.06 | $3.62 |
Technical Indicators
Market Signals| Indicator | VMD | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.70 | 44.05 |
| Support Level | $9.27 | $2.07 |
| Resistance Level | $10.04 | $2.58 |
| Average True Range (ATR) | 0.28 | 0.21 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 68.80 | 23.02 |
Price Performance
Historical ComparisonAbout VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.